

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: DOWER et al.

Serial No.: To be assigned

Filed: Concurrently herewith

For: *PEPTIDES AND COMPOUNDS  
THAT SEND TO A  
THROMBOPOIETIN RECEPTOR*

## BOX PATENT APPLICATION

Commissioner for Patents

Washington, D.C. 20231

10/083768  
02/27/02  
10/083768  
02/27/02

## INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

- ☐ Copies of the references are enclosed
- ☒ Copies of the references were submitted in parent application Serial No. 09 549,090 (37 CFR 1.98(d))
- ☐ A copy of the International Search Report which issued on International Application No. \_\_\_\_\_ is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.
- A. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).
- OR
- ☐ The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).
- B. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but **before** the mailing date of either:
- (1) a final action under § 1.113 or
- (2) a notice of allowance under § 1.311,
- whichever occurs first.
- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$240.00).
- C. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No. \_\_\_\_\_


In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).
- ☐ The petition fee set forth in § 1.17(d)(1) (\$130.00) is submitted herewith.

☒ Please charge any required fees to Deposit Account No.07-1392.

☐ A duplicate copy of this paper is attached.

Respectfully Submitted.

  
\_\_\_\_\_  
Virginia C. Bennett  
Attorney of Record  
Registration No. 37,092

Date: 11/24/92

GlaxoSmithKline  
Corporate Intellectual Property  
5 Moore Drive, P.O. Box 13398  
Research Triangle Park, NC 27709-3398  
Telephone: (919) 483-1012  
Facsimile: (919) 483-7988

<b>FORM PTO-1449</b> <b>INFORMATION DISCLOSURE STATEMENT</b>				<b>ATTORNEY DOCKET</b> NO. PK3065US3		<b>SERIAL NO.</b> To be assigned		U.S. PTO 10/083768 02/27/02		
				<b>APPLICANT</b> Dower et al.						
				<b>FILING DATE</b> Concurrently herewith		<b>GROUP</b>				
<b>U.S. PATENT DOCUMENTS</b>										
Examiner Initials	Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate				
	AA	5,143,854	Pirrung et al.							
	AB	5,270,170	Schatz et al.							
	AC	5,326,558	Turner et al.							
	AD	5,338,665	Schatz et al.							
	AE	5,384,331	Kogan et al.							
	AF	5,358,934A	Borovsky et al.							
	AG	5,141,851A	Brown et al.							
	AH	5,411,942A	Widmer et al.							
	AI	5,932,546	Barrett et al.							
				Continued on page 3						
<b>FOREIGN PATENT DOCUMENTS</b>										
	Document Number	Publication Date	Country	Class	Subclass	Translation Yes   No				
	BA	WO 90/15070	PCT							
	BB	WO 91/07988	PCT							
	BC	WO 91/08752	PCT							
	BD	WO 93/25221	PCT							
	BE	WO 95/11922	PCT							
	BF	WO 95/18858	PCT							
	BG	WO 95/21626	PCT							
	BH	WO 95/21919	PCT							
	BI	WO 95/21920	PCT							
	BJ	WO 95/28907	PCT							
	BK	EP 0 668 352 A1	EPO							
	BL	EP 0 675 201 A1	EPO							
	BM	EP 0 690 127 A1	EPO							
	BN	GB 2 285 446 A	GB							
	BO	WO 96/17062	PCT							
	BP	WO 96/17067	PCT							
	BQ	WO 96/17062 A1	PCT							
<b>OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)</b>										
CA	Barker et al., "Cyclic RGE peptide analogues as antiplatelet antithrombotics", J. Med. Chem., Vol. 35:2040-2048 (1992)									
CB	Bartley et al., "Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl", Cell, Vol. 77:1117-1124 (1994)									
CC	Bazan, "Structural design and molecular evolution of a cytokine receptor superfamily", Proc. Natl. Acad. Sci. USA, Vol. 87:6934-6938 (1990)									
Continued on page 2										

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTORNEY DOCKET NO. PK3065US3	SERIAL NO. To be assigned
		APPLICANT Dower et al.	
		FILING DATE Concurrently herewith	GROUP
	CD	Caras et al., "Signal peptide for protein secretion directing glycopospholipid membrane anchor attachment", Science, Vol. 243:1196-1198 (1989)	
	CE	Cwirla et al., "Peptides on phage: A vast library of peptides for identifying ligands", Proc. Natl. Acad. Sci. USA, Vol. 87:6378-6382 (1990)	
	CF	Dexter et al., "Growth factor-dependent hemopoietic precursor cell lines", J. Exp. Med., Vol. 152:1036-1047 (198)	
	CG	Dower et al., "The search for molecular diversity (II): Recombinant and synthetic randomized peptide libraries", Ann. Rep. Med. Chem., Vol. 26:271-280 (1991)	
	CH	Dower et al., "High efficiency transformation of E.coli by high voltage electroporation", Nucleic Acids Research, Vol. 16:6127 (1988)	
	CI	Fodor et al., "Light-directed, spatially addressable parallel chemical synthesis", Science, Vol. 251:767-773 (1991)	
	CJ	Harker, "Kinetics of thrombopoiesis", J. Clin. Invest., Vol. 47:458-465 (1968)	
	CK	Kaushansky et al., "Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin", Nature, Vol. 369:568-571 (1994)	
	CL	Kojima et al., "Molecular cloning and expression of megakaryocyte potentiating factor cDNA, J. Biol. Chem., Vol. 270:21984-21990 (1995)	
	CM	Kuter et al., "The purification of megapoietin: A physiological regulator of megakaryocyte growth and platelet production", Proc. Natl. Acad. Sci. USA, Vol. 91:11104-11108 (1994)	
	CN	McDonald, "Thrombopoietin - Its biology, clinical aspects and possibilities", Am. J. Pediatric Hematology/Oncology, Vol. 14:8-21 (1992)	
	CO	Metcalf, "Thrombopoietin - at last", Nature, Vol. 369:519-520 (1994)	
	CP	Methia et al., "Oligodeoxynucleotides antisense to the proto-oncogene c-mpl specifically inhibit in vitro megakaryocytopoiesis", Blood, Vol. 82:1395-1401 (1993)	
	CQ	Mossmann, "Rapid colorimetric assays for cellular growth and survival: Application to proliferation and cytotoxicity assays", J. Immunol. Methods, Vol. 65:55-63 (1983)	
	CR	Or et al., "Cysteine alkylation in unprotected peptides: Synthesis of a carbavasopressin analogue by intramolecular cysteine alkylation, J. Org. Chem., Vol. 56:3146-3149 (1991)	
	CS	de Sauvage et al., "Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand", Nature, Vol. 369:533-538 (1994)	
	CT	Souyri et al., "A putative truncated cytokine receptor gene transduced by the myeloproliferative leukemia virus immortalizes hematopoietic progenitors, Cell, Vol. 63:1137-1147 (1990)	
	CU	Vigon et al., "Molecular cloning and characterization of MPL, the human homolog of the v-mpi oncogene: Identification of a member of the hematopoietic growth factor receptor superfamily", Proc. Natl. Acad. Sci. USA, Vol. 89:5640-5644 (1992)	
	CV	Verber et al., "The design of metabolically-stable peptide analogs", Trends in Neurosciences (TINS), pgs. 392-396 (1990)	
	CW	Wendling et al., "The oncogene V-MPL, A putative truncated cytokine receptor which immortalizes hematopoietic progenitors", I. Inserm, pgs. 145-146 (1992)	
	CX	Wendling et al., "c-Mpl ligand is a humoral regulator of megakaryocytopoiesis, Nature:571-574 (1994)	
	CY	Kato et al., "Purification and Characterization of Thrombopoietin", J. Biochem, Vol. 118:229-236 (1995)	
	CZ	Wada et al., "Characterization of the Truncated Thrombopoietin Variants", Biophysical Research Communications, Vol. 213:1091-1098 (1995)	

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

FORM PTO-1449

## INFORMATION DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.  
PK3065US3SERIAL NO.  
To be assignedAPPLICANT  
DOWER et al.FILING DATE  
Concurrently herewith

GROUP

## U.S. PATENT DOCUMENTS

Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	AJ	5,869,451	02-1999	DOWER et al.	514	13	
	AK	6,083,913	07-2000	DOWER et al.	514	13	

Continue on page \_\_\_\_\_

## FOREIGN PATENT DOCUMENTS

		Document Number	Publication Date	Country	Class	Subclass	Translation Yes   No

Continue on page \_\_\_\_\_

## OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)


Continue on page \_\_\_\_\_

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.